問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chi Mei Medical Center

Recruiting

List

145Cases

2025-01-01 - 2030-01-31

Phase III

Active
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non- alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis

  • Condition/Disease

    cirrhosis

  • Test Drug

    N/A

Participate Sites
11Sites

Recruiting11Sites

2019-06-01 - 2024-09-30

Phase III

Completed
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy and safety of tislelizumab (BGB-A317) in combination with chemotherapy as first-line treatment in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Condition/Disease

    unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Test Drug

    BGB-A317

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

林振源
China Medical University Hospital

Division of Hematology & Oncology

2019-09-15 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-09-01 - 2029-05-25

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-16 - 2028-10-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-04-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-09-16 - 2026-12-31

Phase III

Completed
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

  • Condition/Disease

    Type 1 Diabetes

  • Test Drug

    LY3209590/Basal Insulin - Fc (BIF)

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

  • Condition/Disease

    Non–small cell lung cancer (NSCLC)

  • Test Drug

    Durvalumab Olomorasib Pembrolizumab

Participate Sites
18Sites

Recruiting18Sites

2025-09-30 - 2032-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

1 7 8 9 10 11 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB